

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

Ruth Wester,¹ Bronno van der Holt,² Emelie Asselbergs,¹ Sonja Zweegman,³ Marie Jose Kersten,² Edo Vellenga,⁴ Marinus van Marwijk Kooy,⁵ Okke de Weerd,⁶ Monique Minnema,⁷ Sarah Lonergan,¹ Antonio Palumbo,⁸ Henk Lokhorst,³ Annemiek Broijl¹ and Pieter Sonneveld¹

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; ²HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; ³Department of Hematology, Amsterdam UMC, Amsterdam, the Netherlands; ⁴Department of Hematology, University Medical Center Groningen, University of Groningen, the Netherlands; ⁵Department of Hematology, Isala Clinics, Zwolle, the Netherlands; ⁶Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands; ⁷Department of Hematology, UMC Utrecht Cancer Center, Utrecht, the Netherlands and ⁸Department of Hematology, University of Torino, Torino, Italy

©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.205476

Received: September 2, 2018.

Accepted: March 28, 2019.

Pre-published: April 4, 2019.

Correspondence: RUTH WESTER - r.wester@erasmusmc.nl.

Supplementary data:

Table S1. Treatment-emergent adverse events during therapy.

Toxicity, n (%)	Induction therapy (N=111)		Induction and consolidation therapy (N=111)		
	Any grade	Grade 3/4	Any grade	Grade 3/4	SAE
Hematologic	7 (6)	5 (5)	17 (15)	11 (10)	3 (3)
Anemia	5 (5)	4 (4)	9 (8)	4 (4)	0 (0)
(Febrile) Neutropenia	1 (1)	1 (1)	2 (2)	2 (2)	0 (0)
Thrombopenia	0 (0)	0 (0)	5 (5)	5 (5)	2 (2)
Leukopenia	1 (1)	0 (0)	3 (3)	0 (0)	0 (0)
Other	1 (1)	1 (1)	2 (2)	1 (1)	1 (1)
Non-hematologic	110 (99)	42 (38)	110 (99)	51 (46)	57 (51)
General disorders and administration site conditions	67 (60)	2 (2)	77 (69)	3 (3)	10 (9)
Gastrointestinal disorders	59 (53)	3 (3)	64 (58)	3 (3)	6 (5)
Respiratory, thoracic, and mediastinal disorders	37 (33)	7 (6)	51 (46)	9 (8)	4 (4)
PNP	43 (39)	0 (0)	50 (45)	0 (0)	0 (0)
Skin and subcutaneous tissue disorders	43 (39)	9 (8)	45 (41)	10 (9)	2 (2)
Musculature, skeletal, and connective tissue disorders	34 (31)	5 (5)	48 (43)	7 (6)	1 (1)
Vascular disorders	34 (31)	9 (8)	35 (32)	10 (9)	7 (6)
Cardiac disorders	15 (14)	4 (4)	19 (17)	5 (5)	6 (5)
Infections and infestations	26 (23)	2 (2)	47 (42)	6 (5)	12 (11)
Metabolism and nutrition disorders	19 (17)	10 (9)	21 (19)	10 (9)	5 (5)
Investigations	12 (11)	5 (5)	13 (12)	6 (5)	0 (0)
Eye disorders	13 (12)	1 (1)	18 (16)	1 (1)	0 (0)
Psychiatric disorders	8 (7)	0 (0)	12 (11)	0 (0)	0 (0)
Renal and urinary disorders	9 (8)	3 (3)	12 (11)	3 (3)	2 (2)
Endocrine disorders	2 (2)	1 (1)	2 (2)	1 (1)	0 (0)
Surgical and medical procedures	1 (1)	1 (1)	2 (2)	1 (1)	1 (1)
Immune system disorders	3 (3)	2 (2)	4 (4)	2 (2)	1 (1)

Table 1. Treatment-emergent adverse events during induction and consolidation therapy, excluding cyclophosphamide and HDM.

Table S2. Adherence to treatment protocol during induction and consolidation between dose levels.

	Induction				Consolidation			
	20/27 mg/m ²	20/36 mg/m ²	20/45 mg/m ²	20/56 mg/m ²	20/27 mg/m ²	20/36 mg/m ²	20/45 mg/m ²	20/56 mg/m ²
Patients (n)	50	20	21	20	41	15	19	19
Carfilzomib								
Normal completion	29 (58)	13 (65)	12 (57)	15 (75)	29 (71)	8 (53)	14 (74)	10 (53)
Dose delay, reduction and/or interruption	17 (34)	6 (30)	9 (43)	4 (20)	11 (27)	6 (40)	3 (16)	4 (21)
Premature stop	4 (8)	1 (5)	-	1 (5)	1 (2)	1 (7)	2 (11)	5 (26)
Thalidomide								
Normal completion	29 (58)	15 (75)	5 (24)	7 (35)	32 (78)	12 (80)	12 (63)	7 (37)
Dose delay, reduction and/or interruption	15 (30)	4 (20)	14 (67)	10 (50)	3 (7)	-	2 (11)	3 (16)
Premature stop	6 (12)	1 (5)	2 (10)	3 (15)	6 (15)	3 (20)	5 (26)	9 (47)
Dexamethasone								
Normal completion	38 (76)	18 (90)	15 (71)	14 (70)	31 (76)	11 (73)	13 (68)	11 (58)
Dose delay, reduction and/or interruption	8 (16)	1 (5)	6 (29)	5 (25)	8 (20)	3 (20)	4 (21)	3 (16)
Premature stop	4 (8)	1 (5)	-	1 (5)	2 (5)	1 (7)	2 (11)	5 (26)